Neos Therapeutics, Inc. (NEOS) SEC Filing 8-K Material Event for the period ending Tuesday, October 23, 2018

Neos Therapeutics, Inc.

CIK: 1467652 Ticker: NEOS

View differences made from one to another to evaluate Neos Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Neos Therapeutics, Inc..


Assess how Neos Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Neos Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Neos Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: NEOS
CIK: 1467652
Form Type: 8-K Corporate News
Accession Number: 0001104659-18-063669
Submitted to the SEC: Wed Oct 24 2018 4:16:02 PM EST
Accepted by the SEC: Wed Oct 24 2018
Period: Tuesday, October 23, 2018
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: